Technology Portfolio
Aybar Ecotechnologies develops scalable, IP-secured technologies across energy, biotech, and health. Each project is designed for licensing, strategic deployment, and global impact. This page is the consolidated view; each platform has a full technical page of its own.
Gravitational Modulation Platform
Overview
Aybar’s flagship energy innovation uses laser-based gravitational field control to enable levitating transport, low-energy lift systems, and aerospace propulsion. Patent-pending and designed for OEM integration, this platform addresses mobility and infrastructure at the level of the physics rather than the mechanism.
Technical Highlights
- Modular, surface-integrated architecture rather than a discrete engine
- Grounded in the EMG Theory of the Photon, published 1992
- Status: prototype, patent-pending, NDA-secured negotiations
Commercial Applications
Aerospace launch assist; transportation and levitation-enabled mobility; gravity-driven power generation; construction, mining, and telecom deployment in terrain-inaccessible locations.
Investor & Partner Opportunities
OEM licensing and development capital to move from prototype to demonstrator. Read the full platform page: Gravity-Modulating Laser Technology
Proprietary Protein Purification Protocol
Overview
A new method for purifying macromolecules with ionic functional groups by high performance liquid chromatography. Purification is 50% to 80% of the production cost of a therapeutic protein; this protocol compresses it without new capital equipment.
Technical Highlights
- Single step replacing a conventional five-step sequence, at 23-fold purification
- 4 to 6 days to process 60 lb of yeast, against 6 months by hydroxylapatite chromatography
- 80 to 90% reduction in buffer use; 8 to 10 times lower dilution
- More than 80 affinity column reuse cycles
- Runs on existing FPLC/HPLC infrastructure; semi-continuous and programmable
Commercial Applications
Functional food ingredients, nutraceuticals, therapeutic proteins, and plant-based proteins. Total addressable market above $700B across those segments; the purification consumables and services market alone is $19B.
Investor & Partner Opportunities
Volume-based licensing, purification-as-a-service, joint ventures with ingredient firms. We will implement the protocol on one of your protein products at no cost, given starting material and facility access. Read the full platform page: Protein Purification Technology
Universal Bactericide Platform
Overview
A lysozyme-based antibacterial platform combining a chelation system and a pH-stabilized formulation, active against gram-positive and gram-negative bacteria through a non-antibiotic mechanism that does not select for resistance.
Technical Highlights
- Comparative clinical study, n=70, against chlorhexidine 0.12% in dental use
- Gingival index reduced to effectively zero; no bleeding sites at 14 days
- No adverse events attributable to the formulation during the study
- Patent MX 433331 granted 23 March 2026, in force to 28 May 2040; patent JP 7768769 granted; USPTO pending
Commercial Applications
Dental and oral care, post-surgical asepsis and wound healing, veterinary health, and respiratory infection control including force health protection. Phase 1 market entry is oral chewables as a DSHEA dietary supplement.
Investor & Partner Opportunities
Licensing and co-development with partners able to develop, register, manufacture, and commercialize. Clinical partners sought for respiratory delivery. Full dossier under NDA. Read the full platform page: Universal Bactericide